Abstract

Simple SummaryThe estrogen and androgen receptors (ER, AR) are key oncogenic drivers and therapeutic targets in breast and prostate cancer, respectively. These receptors bind to DNA and regulate gene expression but emerging evidence indicates that they also play important roles in controlling the process of mRNA translation, which dictates cellular protein production. Here, we review the mechanisms by which abnormal activities of ER and AR can dysregulate mRNA translation in breast and prostate cancer cells. Specifically, we explore how the intricate cellular signalling pathways that keep mRNA translation in check are perturbed by aberrant ER and AR signalling, which can lead to enhanced cancer cell growth. We also discuss the potential of targeting mRNA translation as a strategy to treat patients with breast and prostate cancer.Breast and prostate cancer are the second and third leading causes of death amongst all cancer types, respectively. Pathogenesis of these malignancies is characterised by dysregulation of sex hormone signalling pathways, mediated by the estrogen receptor-α (ER) in breast cancer and androgen receptor (AR) in prostate cancer. ER and AR are transcription factors whose aberrant function drives oncogenic transcriptional programs to promote cancer growth and progression. While ER/AR are known to stimulate cell growth and survival by modulating gene transcription, emerging findings indicate that their effects in neoplasia are also mediated by dysregulation of protein synthesis (i.e., mRNA translation). This suggests that ER/AR can coordinately perturb both transcriptional and translational programs, resulting in the establishment of proteomes that promote malignancy. In this review, we will discuss relatively understudied aspects of ER and AR activity in regulating protein synthesis as well as the potential of targeting mRNA translation in breast and prostate cancer.

Highlights

  • Simple Summary: The estrogen and androgen receptors (ER, AR) are key oncogenic drivers and therapeutic targets in breast and prostate cancer, respectively

  • Mutation of genes implicated in translation regulation and perturbation of translational programs appears to be a common feature of breast cancers (BC)/prostate cancers (PC), which provides a strong rationale for targeting translational machinery in these diseases

  • AR-low PC cells exhibited higher sensitivity to 4EBP1 over-expression as compared to corresponding models with high levels of AR [30]. These findings suggest that the absence of AR can promote protein synthesis, and that the effects of AR on translation may be mediated via regulation of 4EBP1/eIF4F

Read more

Summary

Translation Initiation

2. Dysregulation of Translation Is a Common Feature of Cancer of mRNAs can be broadly divided into four steps: initiation, elongation, 2.1. Translation Initiation termination and ribosome recycling [12]. The initiation and elongation steps of translation. Translation of mRNAs can be broadly divided into four steps: initiation, elongation, are thought and to be the most highly regulated andand have steps been ofstudied most intentermination ribosome recycling [12]. Dysregulation of translation in cancer, which of alterations in are thought to be the most highly regulated and have beenoccurs studiedbecause most intensively the levels or the activity of the components of translational [14], canlevimpact any [13]. Dysregulation of translation in cancer, which occurs becausemachinery of alterations in the ofels these steps. The activity of the components of translational machinery [14], can impact any of these steps

Amajor prominent feature of many are mutations thatare lead to activation
Translation Elongation
Genomic Alterations to Translation Factors in Breast and Prostate Cancer
ER Selectively Controls Translation Initiation
ER Is an Important Player in the UPR
AR Indirectly Regulates Translation Initiation
AR and UPR
Targeting Pathways That Regulate mRNA Translation
Targeting Ribosome Biogenesis
Targeting the UPR
Drawbacks and New Hopes in Treatments Targeting mTOR in BC and PC
Findings
The Future of mTOR Inhibition as a Therapy for Breast and Prostate Cancer

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.